Coya Therapeutics Inc. Common Stock (COYA)

About COYA

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration inte…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

8

Website

www.coyatherapeutics.com/

Fundamentals

1-day range

$4.55$4.82

Market cap

$107.43M

P/E (trailing)

—

P/E (forward)

-2.44

EPS (trailing)

$-1.15

Dividend yield

—

Beta

0.64

Avg. volume

195.0K

Forecasts

7 analyst ratings

Coya Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• COYA

  Coya Therapeutics Inc. Common Stock

  $4.59

  ▼ 5.56%
  Market cap $107.43MP/E —
  $3.71$7.75
• RFL

  Rafael Holdings Inc. Class B Common Stock

  $2.52

  ▲ 6.33%
  Market cap $105.04MP/E —
  $1.12$3.96
• PLYX

  Polaryx Therapeutics Inc. Common Stock

  $2.07

  ▼ 2.13%
  Market cap $110.66MP/E —
  $1.86$48.91
• NRXP

  NRX Pharmaceuticals Inc. Common Stock

  $3.54

  ▼ 2.21%
  Market cap $111.95MP/E —
• RANI

  Rani Therapeutics Holdings Inc. Class A Common Stock

  $0.845

  ▼ 1.05%
  Market cap $96.76MP/E —
  $0.44$3.87
• BGM

  BGM Group Ltd. Class A Ordinary Shares

  $0.3251

  ▲ 11.34%
  Market cap $118.62MP/E —
  $0.2287$11.8
• ALDX

  Aldeyra Therapeutics Inc. Common Stock

  $1.49

  ▼ 3.57%
  Market cap $95.91MP/E —
  $1.07$6.18

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Roth Capital Reiterates Buy on Coya Therapeutics, Maintains $12 Price Target
  benzinga · 8/24/2026
• Roth Capital Reiterates Buy on Coya Therapeutics, Maintains $12 Price Target
  Benzinga · 8/24/2026
• Coya Therapeutics Q2 EPS $(0.28) Beats $(0.34) Estimate, Sales $243.745K Beat $100.000K Estimate
  Benzinga · 8/11/2026

• Pavao Mark H · April 9, 2026 · Grant

  10.0K

Institutional Ownership

March 31, 2026

Total shares held

8.05M

Total value held

$31.65M

Institutional holders

54